Enanta Pharmaceuticals IPO Advisory
Share this IPO Profile:
Smart Search
For IPO Boutique's "scale of 1 to 5" BUY rating on Enanta Pharmaceuticals, and our comprehensive analysis, click "
Buy Market Research".
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
Enanta Pharmaceuticals | ENTA - NASDAQ |
$14.00-$16.00 |
$14.00 |
$14.31 | 4 million | 3/21/2013 |
J.P. Morgan, Credit Suisse |
Co-Manager(s): Leerink Swann, JMP Securities |
Health Care |
Filing(s): Filed 2012-11-06
|
Enanta Pharmaceuticals Quote & Chart - Click for current quote -
ENTA
About Enanta Pharmaceuticals (adapted from Enanta Pharmaceuticals prospectus):
They are a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "ENTA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
© 2005 - 2025 IPO Boutique. All Rights Reserved